Targeted Drug Nanocarrier Platform NanoCargo Receives FDA Approval: Chemotherapy Delivered Directly to Tumor Cells with 90% Fewer Side Effects

The US FDA approved Swiss pharmaceutical giant Novartis and MIT's Koch Institute for Integrative Cancer Research to enter Phase III clinical trials for their jointly developed NanoCargo nanodrug delivery platform on July 19. The platform uses surface-modified lipid nanoparticles (LNP) as carriers, triggering drug release through the tumor microenvironment's unique pH levels and enzyme activity, achieving 8.7 times higher drug concentration at the tumor site compared to conventional administration.

In completed Phase II trials involving 142 patients with advanced non-small cell lung cancer, NanoCargo-delivered paclitaxel achieved an objective tumor response rate of 61%, compared to 34% in the traditional intravenous injection group. More critically, the rate of grade 3 or higher adverse reactions in the NanoCargo group was only 12%, compared to 47% in the control group, with typical chemotherapy side effects like bone marrow suppression and neurotoxicity significantly reduced.

MIT Koch Institute director Professor Angela Belcher stated: "NanoCargo's core innovation lies in its dual-trigger mechanism — nanoparticles remain stable during normal blood circulation and release drugs only when simultaneously detecting the tumor's acidic environment and specific matrix metalloproteinases."

Novartis expects the annual treatment cost for NanoCargo to be around $85,000, comparable to current immunotherapy costs. The company plans to extend the NanoCargo technology to breast and pancreatic cancer indications by 2030.

However, the FDA noted in its approval documents that long-term safety data for NanoCargo still requires continuous monitoring, and the cumulative effects of nanomaterials in the body remain a key regulatory concern.